AFAude A. Ferran

Aude A. Ferran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aude A. Ferran has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Limited and transient effects of intramuscular benzylpenicillin on the equine gut microbiota and resistome

    by Véronique Dupouy, Annabelle Meynadier, Nathalie Arpaillange, Lucas Cordon, Sandra Simoes-Lourenço, Juliette F. Monbrun, Aude A. Ferran, Elodie A. Lallemand

  • Open Access

    Quantitative Pharmacodynamic Analysis of Trimethoprim‐Sulfonamide Combination Activity Against Staphylococcus pseudintermedius

    by Andrew Mead, Alexis Viel, Marine Boulanger, Gudrun Overesch, Carl Ekstrand, Pierre‐Louis Toutain, Aude A. Ferran, Ludovic Pelligand

    Trimethoprim (TMP)‐sulfonamide combinations are widely used in veterinary medicine, yet the quantitative nature of their pharmacodynamic interaction remains incompletely characterised. This study investigated the interaction between TMP and sulfamethoxazole (SMX), sulfadiazine (SDZ) and sulfadimethoxine (SDMX) against two Staphylococcus pseudintermedius isolates using minimum inhibitory concentration (MIC) testing, time‐kill curve (TKC) experiments and semi‐mechanistic pharmacodynamic modelling incorporating a General Pharmacodynamic Interaction (GPDI) framework. TKC assays demonstrated enhanced antibacterial activity for TMP‐sulfonamide combinations compared with monotherapy, with the greatest bacterial killing observed at TMP:sulfonamide ratios of 1:4 and 1:19. The final GPDI model identified a predominantly unidirectional interaction in which sulfonamides increased TMP potency through concentration‐dependent reductions in TMP EC 50 of 86%–96% at saturating sulfonamide concentrations, corresponding to approximately 7‐ to 26‐fold maximal possible increases in TMP potency. Maximal synergy differed between sulfonamides, occurring at approximately 1:20 for TMP/SMX (~75% increase in killing), 1:40 for TMP/SDZ (~181%) and 1:5 for TMP/SDMX (~80%). Pharmacokinetic‐pharmacodynamic simulations of clinically relevant canine dosing regimens predicted transient bacterial suppression but not bacterial eradication. These findings demonstrate that TMP‐sulfonamide synergy is dynamic, concentration‐dependent and bacterial species‐specific, highlighting the importance of PK/PD‐informed optimisation of potentiated sulfonamide therapy in veterinary medicine.

  • Open Access

    Population pharmacokinetic modeling of sulfamethoxazole, sulfadiazine and sulfadimethoxine combined with trimethoprim in calves

    by Marine Boulanger, Béatrice B. Roques, Marlène Z. Lacroix, Lucie Claustre, Mathias Devreese, Siegrid De Baere, Alexis Viel, Aude A. Ferran

  • Open Access

    Population pharmacokinetic modeling of sulfadimethoxine, sulfadiazine and sulfamethoxazole combined to trimethoprim in pigs

    by Marine Boulanger, Jean-François Taillandier, Jérôme Henri, Mathias Devreese, Siegrid De Baere, Marlène Lacroix, Aude A. Ferran, Alexis Viel

    Sulfonamides (S) are old antibiotics combined with trimethoprim (TMP) for synergistic effects against pathogens responsible for a variety of infections in food-producing animals. In growing pigs, the TMP:S ratio is 1:5 based on human TMP/sulfamethoxazole (SMX) dosing which aims to obtain an in vivo ratio concentration of 1:19 considered as optimal against human pathogens. However, different sulfonamides with different pharmacokinetic profiles are used in pigs limiting this direct extrapolation from human. The aim was to conduct a PK study in pigs for three commonly used TMP/S combinations and to analyze data using population pharmacokinetic modeling. We found that a 2-compartment structural model fitted best the four drug PK data. TMP has the highest clearance values (0.48 L/h/kg) compared to SMX (0.21 L/h/kg), SDZ (0.12 L/h/kg) and SDMX (0.015 L/h/kg). SDMX has the longest plasma elimination half-life (14.8 h), followed by SDZ (3.7 h), TMP (2.9 h) and SMX (2.2 h). Monte Carlo simulations (n = 50,000 pigs) showed that only for 8.8%, 46.8%, and 76.5% of pigs for TMP/SMX, TMP/SDZ and TMP/SDMX, respectively, the free plasma concentration ratio fell within the range of 1:10-1:50 at the marketed doses administered. These results should be further linked to pharmacodynamics to optimize the use of these important antimicrobials drugs in veterinary medicine.


  • Open Access

    Reassessment of extracellular and intracellular activity of macrolides, rifampicin, and doxycycline against Rhodococcus equi based on bacterial counts and microscopy

    by Anne-Sophie Huguet, Ophélie Gourbeyre, Alain Bousquet-Mélou, Aude A. Ferran, Elodie A. Lallemand

    Rhodococcus equi is an opportunistic intracellular pathogen responsible for severe respiratory infections in foals, requiring prolonged antibiotic treatment. Despite its in vitro susceptibility to multiple antibiotics, the in vivo eradication of intracellular R. equi remains challenging due to its ability to persist and survive within alveolar macrophages. This study aimed to assess in vitro the extracellular and intracellular activity of rifampicin, doxycycline, and four macrolides against R. equi while assessing current methodologies used to differentiate intracellular and extracellular bacteria. We found that the removal of extracellular R. equi with short times of exposure to bactericidal drugs was challenging. We thus proposed an alternative approach with washing steps to assess intracellular antibiotic activity by combining bacterial counts and optical microscopy. Our results indicated that clarithromycin alone, as well as azithromycin or gamithromycin in combination with doxycycline, dramatically reduced both intracellular and extracellular R. equi . This study also highlighted the need for refined in vitro methodologies to assess antibiotic efficacy against R. equi, ultimately contributing to the development of optimized treatment strategies for R. equi infections in foals. IMPORTANCE: Rhodococcus equi is a major cause of pneumonia in foals and represents a serious challenge for the equine sector due to the need for prolonged and sometimes ineffective antibiotic treatments. This study highlights the limitations of current in vitro methods used to evaluate antibiotic activity against R. equi , by demonstrating that widely used bactericidal antibiotics like gentamicin may not eliminate extracellular bacteria as effectively as previously assumed, and we emphasize the risk of overestimating intracellular bacterial survival in experimental models. We therefore propose a new method that allows more accurate assessment of antibiotic efficacy within host cells. Our findings help refine in vitro testing strategies and support the identification of antibiotic combinations with effective intracellular activity, offering new perspectives for improving treatment protocols against R. equi infections in foals.


  • Open Access

    Pharmacokinetic–Pharmacodynamic Cutoff Values for Doxycycline in Pigs to Support the Establishment of Clinical Breakpoints for Antimicrobial Susceptibility Testing

    by Pierre‐Louis Toutain, Alain Bousquet‐Melou, Aude A. Ferran, Béatrice B. Roques, Jérôme R. E. del Castillo, Peter Lees, Siska Croubels, Eric Bousquet, Ludovic Pelligand

    This meta‐analysis provides a population model of doxycycline (DOXY) disposition in pigs for computation of PK/PD cutoff values corresponding to differing modalities of DOXY administration orally in pigs. This analysis enables establishment of specific clinical breakpoints for the development of antimicrobial susceptibility testing of DOXY in pigs. The meta‐analysis of 380 data sets, totaling 3295 plasma concentrations obtained from 300 pigs weighing 8.5–101 kg, was performed using a non‐linear mixed effect model. The plasma clearance for a typical 50 kg BW pig was estimated to be 0.259 L/kg/h with a corresponding plasma half‐life of 7.33 h. The bioavailability of DOXY administered in feed under field conditions was estimated to be 50%, with a large between‐subject variability of 84.8%. The bioavailability of DOXY in solution in drinking water was significantly lower (30.7%) but much less variable, with a between‐subject variability of 34.3%. Several dosing schedules (5 to 20 mg/kg per day) for two administration modalities (drinking water vs. food) were simulated to calculate the corresponding PK/PD cutoffs. The highest PK/PD cutoff of 0.50 mg/L was obtained for DOXY administered in feed at 20 mg/kg BW.


  • Open Access

    Comparative bactericidal activity of four macrolides alone and combined with rifampicin or doxycycline against Rhodococcus equi at concentrations achievable in foals

    by Anne-Sophie Huguet, Ophélie Gourbeyre, Agathe Bernand, Charline Philibert, Alain Bousquet-Melou, Elodie A. Lallemand, Aude A. Ferran

    Introduction: Rhodococcus equi causes life-threatening respiratory disease in foals. The standard treatment typically involves a combination of rifampicin and a macrolide antibiotic. Although previous studies have demonstrated the in vitro activity of these antibiotics against Rhodococcus equi, the tested concentrations often do not reflect those achievable in foals.Material and Methods: Therefore, this study was performed to evaluate the in vitro bactericidal activity of rifampicin, doxycycline, and four macrolides (clarithromycin, azithromycin, gamithromycin and tulathromycin) individually and in combination, at concentrations observed at the target site of infection in foals. Additionally, we investigated the efficacy of these antibiotics at different pH levels to replicate the conditions in the pulmonary epithelial lining fluid and within macrophages, where R. equi can reside. We assessed the activity of antibiotics against a virulent strain of R. equi by determining the minimum inhibitory concentration (MIC) and performing checkerboard and time-kill curve assays with drugs both alone and in combination.Results: Time-kill curves with rifampicin or doxycycline demonstrated a reduction in R. equi counts by more than 3 log10 CFU/mL. Among the macrolides, tulathromycin was ineffective, while clarithromycin achieved bacterial elimination within 24 h under both extracellular and intracellular conditions. Gamithromycin and azithromycin exhibited bactericidal activity only in extracellular conditions, with no effect on the bacteria at pH 5.8. The checkerboard assay did not reveal any strong synergistic or antagonistic effects for rifampicin or doxycycline when combined with macrolides. In time-kill curves performed with maximal local concentrations achievable in foals, the combinations of rifampicin or doxycycline with macrolides did not increase the bacterial killing rate compared with the drugs alone, except for the combination of rifampicin with azithromycin, which showed slightly faster activity. However, the lower concentrations of doxycycline and clarithromycin that might be present 24 h after treatment in foals were effective in killing bacteria under intracellular conditions only when used in combination, and not when used alone.Conclusion: Our study suggests that clarithromycin can be used either alone or with doxycycline and that its use in combination with rifampicin should be reconsidered. Nevertheless, further studies are required to assess the clinical efficacy and potential side effects of doxycycline in foals.


  • Open Access

    Pharmacokinetic modeling of sulfamethoxazole-trimethoprim and sulfadiazine-trimethoprim combinations in broilers

    by Marine Boulanger, Jean-François Taillandier, Jérôme Henri, Mathias Devreese, Siegrid De Baere, Aude A. Ferran, Alexis Viel


  • Open Access

    Antimicrobial combinations against Helicobacter pylori including benzoxadiazol-based flavodoxin inhibitors: in vitro characterization

    by Lilha Beyria, Ophelie Gourbeyre, Sandra Salillas, Alejandro Mahía, María Dolores Díaz de Villegas, José Antonio Aínsa, Javier Sancho, Alain Bousquet-Mélou, Aude A. Ferran

    Antimicrobial resistance of Helicobacter pylori ( Hp ) threatens currently available treatment regimens and prompts the development of antimicrobial drugs against new bacterial targets. One such class of drugs is Hp -flavodoxin ( Hp -fld) inhibitors, which target an essential metabolic pathway in Hp . The aim of this study was to characterize the effects of these inhibitors against Hp over time when used alone or combined with conventional antibiotics. Four benzoxadiazol-based fld inhibitors were initially tested for their in vitro potency, with compound IV displaying the highest efficacy. This compound was then combined with clarithromycin, metronidazole, amoxicillin, levofloxacin, and rifampicin in further experiments. Checkerboard assays indicated that compound IV exhibited additive activity when combined with these antibiotics. The study further investigated the time course of antibacterial effects by exposing a high inoculum of Hp to compound IV and each antibiotic, alone or in combination. At just four times the minimum inhibitory concentration, compound IV demonstrated bactericidal effects within 6 h. However, the regrowth of bacteria occurred between 24 and 48 h of exposure. Similar patterns of killing followed by regrowth were observed for conventional antibiotics alone. However, the addition of compound IV to the antibiotics clearly limited regrowth over 72 h. These findings suggest that compound IV can effectively eliminate spontaneous mutants that are resistant to conventional antibiotics or prevent new mutations during drug exposure. Hp -fld inhibitors, such as compound IV, hold promise as new drugs to be integrated into Hp infection treatment, potentially reducing the development of resistance and shortening the duration of treatment. IMPORTANCE: The antimicrobial resistance of Helicobacter pylori ( Hp ) currently poses a threat to available treatment regimens. Developing antimicrobial drugs targeting new bacterial targets is crucial, and one such class of drugs includes Hp -flavodoxin ( Hp -fld) inhibitors that target an essential metabolic pathway in Hp . Our study demonstrated that combining these new drugs with conventional antibiotics used for Hp infection treatment prevented the regrowth observed with drugs used alone. Hp -fld inhibitors show promise as new drugs to be incorporated into the treatment of Hp infection, potentially reducing the development of resistance and shortening the treatment duration.


  • Open Access

    The Selection of Antibiotic- and Bacteriophage-Resistant Pseudomonas aeruginosa Is Prevented by Their Combination

    by Aude A. Ferran, Marlène Z. Lacroix, Ophélie Gourbeyre, Alicia Huesca, Baptiste Gaborieau, Laurent Debarbieux, Alain Bousquet-Mélou

    In the treatment of bacterial infections, the use of antibiotics or bacteriophages (phages) is limited by the ability of bacteria to develop resistance. The resistance frequency depends on the exposure to antibacterials.